News

Abpro and Celltrion Unveil Promising HER2×CD3 Antibody Progress

Abpro and Celltrion Unveil Promising HER2×CD3 Antibody Progress

Abpro and Celltrion Highlight CT-P72/ABP-102 Advances

Abpro Corporation (Nasdaq: ABP) and Celltrion, Inc. are thrilled to announce groundbreaking advancements concerning their investigational tetravalent bispecific antibody, CT-P72/ABP-102, which targets HER2 and CD3. The latest preclinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, which takes place soon.

Key Highlights from the Preclinical Data

The upcoming presentation features CT-P72/ABP-102, boasting an impressive selection in the Top 150 abstracts out of more than 1,300 submissions for this meeting. This selection reflects the innovative nature and promising results associated with the antibody, especially against HER2-high models.

Significant Findings

  • Targeted Efficacy: The antibody demonstrates enhanced anti-tumor capabilities in HER2-high settings, particularly in tumors that are known to resist existing therapies.
  • Minimized Off-Target Effects: Thanks to dual-affinity engineering, CT-P72/ABP-102 shows a marked decrease in off-target activity, significantly contributing to its safety profile.
  • Potential for Wider Applications: The versatility of CT-P72/ABP-102 opens doors for clinical development concerning various HER2-positive cancers, indicating a major step forward in oncology treatment.

Future Presentation Details

Hyunkyu Choi from Celltrion will present the poster titled "CT-P72/ABP-102: A dual affinity engineered HER2/CD3 tetravalent bispecific antibody with potential to overcome therapeutic barriers in HER2 high tumors with distinct potency, safety, and selectivity" during the poster session at the SITC event.

This presentation is set for Friday, taking place from 9:00 a.m. to 6:35 p.m. in the Prince George’s ABC Ballroom, where researchers and industry leaders will have the opportunity to discuss these promising therapeutic advancements.

Collaboration Insights

In a recent statement, Miles Suk, Chief Executive Officer of Abpro, expressed strong enthusiasm for the data emerging from their collaboration with Celltrion. He highlighted the antibody's capability to foster significant anti-tumor responses in challenging environments, particularly Enhertu-resistant models.

Through their DiversImmune platform, the team has shown their commitment to developing safer, effective, and precise treatments for patients grappling with HER2-driven cancers worldwide.

Further Developments

Soo Young Lee, Executive Vice President at Celltrion, noted that the advancements observed with CT-P72/ABP-102 could redefine treatment protocols for solid tumors. The thoughtful integration of dual-affinity techniques promises to lower the risks associated with traditional immunotherapy approaches.

Both companies are poised for a robust clinical pathway, intending to submit an IND package in the near future to advance CT-P72/ABP-102 into first-in-human trials.

Conclusion: A New Era for HER2+ Cancer Therapy

The developments surrounding CT-P72/ABP-102 reflect the innovative spirit driving modern cancer therapies. As Abpro and Celltrion progress toward clinical applications, the data suggest a bright future for targeted therapies that reconcile efficacy and safety in the fight against HER2-positive cancers.

Frequently Asked Questions

What is CT-P72/ABP-102?

CT-P72/ABP-102 is a bispecific antibody that targets HER2 and CD3, developed by Abpro and Celltrion to enhance anti-tumor activity while minimizing off-target effects.

What are the key advantages of this new treatment?

The treatment showcases selective binding to tumor cells, enhanced anti-tumor activity, and a favorable safety profile, making it a promising option for HER2-positive cancers.

When will CT-P72/ABP-102 be available for clinical trials?

The companies aim to submit an Investigational New Drug (IND) application soon, with hopes to initiate first-in-human trials shortly afterward.

What is the significance of SITC 2025 in the context of this research?

SITC 2025 serves as a vital platform for presenting new findings in immunotherapy, allowing researchers and clinicians to share insights and advancements like those from CT-P72/ABP-102.

How does this therapy differ from existing treatments?

CT-P72/ABP-102 distinguishes itself with dual-affinity and tetravalent engineering, aiming to provide effective treatment in settings resistant to standard therapies while ensuring patient safety.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovative Trial Targets Drug Resistance in Lung Cancer

Updated Category News Views 53

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Continue Reading
Eric Dalton: Redefining Homecare with Vision and Strategy

Updated Category News Views 59

What's Behind Eric Dalton's Continued Recognition? Now, if you told me a healthcare leader’s named 'Visionary of the Year' twice in a row, my first thought isn't 'stretch goals' but 'show me the goods.' And that’s precisely what Eric J. Dalton has done. The Vice President at Angels on Call Homecare isn't just tooting his own horn; he's building a damn symphony in the...

Continue Reading
Software Updates Costly: UX Not the Biggest Culprit

Updated Category News Views 109

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 37

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
AppGate Rises as 2026 Leader in Digital Risk

Updated Category News Views 67

AppGate: Forging a Path in Digital Security In a world where cyber threats seem to lurk around every digital corner, snagging the title of a leader in digital risk protection from the SPARK Matrix is no small feat. Let’s dive deep into AppGate’s rise to the top in QKS Group’s 2026 evaluation. What Sets AppGate Apart? AppGate's leadership status isn't some overnight...

Continue Reading
McKinsey and Parloa Join Forces on AI Customer Service

Updated Category News Views 60

AI-Revolutionizing Customer Service: The New Partnership Out of the boardroom and into the trenches, McKinsey joins hands with Parloa, aiming to reshape how enterprises handle customer service through artificial intelligence. Forget all the corporate fluff you've heard before; these guys are dead set on closing the massive gap companies face in deploying AI agents...

Continue Reading
Fannie Mae Q3 2026 Earnings Surpass Expectations

Updated Category News Views 35

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

Continue Reading
BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 65

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
BetaNXT and Pave Finance Transform Wealth Management

Updated Category News Views 52

AI Takes Center Stage in Wealth Management You know, it's not every day we see two powerhouses like BetaNXT and Pave Finance buddying up to shake up the financial advisory world. This partnership's all about harnessing AI to give wealth management firms and financial advisors some serious firepower in portfolio planning. BetaNXT, already a big name with its slick...

Continue Reading
Getlabs Brings GI Test Kits to Your Doorstep

Updated Category News Views 106

Home Testing: A Game Changer for GI Patients Imagine dragging yourself out of bed, managing gut issues, only to face a grueling trip to a lab. It's the last thing a patient with GI symptoms wants. Enter Getlabs and Genova Diagnostics with a welcome shift: a partnership that promises to bring the lab to your doorstep—literally. The Partnership Expansion Getlabs, the...

Continue Reading

Top 5 Most Recently Viewed Articles

Infortar's Share Buyback Strategy and Recent Transactions

Updated Category News Views 176

Infortar's Share Buyback Strategy Infortar is actively engaging in a share buyback program on the Nasdaq Tallinn Stock Exchange. This initiative reflects a strategic approach towards securing and stabilizing their market presence. During a recent period, Infortar made notable acquisitions of its own shares, an activity that signals confidence in its long-term value....

Continue Reading
Cisco's Stock Surges to New Heights Amid Innovative Growth

Updated Category News Views 349

Cisco Sets New Milestone with 52-Week High Cisco Systems Inc (NASDAQ: CSCO) has achieved a remarkable milestone as its shares soared to a 52-week high of $60.23. This surge reflects the company's impressive growth trajectory and consistent performance over the past year. With a current market capitalization of $239.6 billion, analysts suggest that the stock may be...

Continue Reading
Insight into Life Science REIT Plc's Recent Disclosure Process

Updated Category News Views 124

Understanding the Disclosure Process for Life Science REIT Plc The disclosure of relevant securities for companies listed on the stock exchange is crucial for maintaining transparency and regulatory compliance. One important example is the recent public opening position disclosure by Life Science REIT Plc, a notable name in the real estate investment trust sector. This...

Continue Reading
November Energy Stocks Worth Watching: High Potential Picks

Updated Category News Views 874

Opportunities in Oversold Energy Stocks In the energy sector, there is often potential for long-term gains hidden within oversold stocks. When a stock exhibits an oversold condition, it's usually an indicator that investor sentiment has driven the price down more than justified by the company's fundamentals. This presents a buy opportunity for savvy investors....

Continue Reading
Terranet's Technology Development Progress Report

Updated Category News Views 104

Terranet's Technology Development Progress Report Recently, Terranet has shared updates with stakeholders regarding its advancements in technology during the second quarter. The company has begun the initial integration of its system into a vehicle, which will lead to an expanded testing phase that will be reported back to the market. The analyses confirm that the ongoing...

Continue Reading